{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:22:12Z","timestamp":1794014532646,"version":"4.8.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>MLLT10 gene rearrangements with KMT2A occur in pediatric acute myeloid leukemia (AML) and confer poor prognosis, but the prognostic impact of MLLT10 in partnership with other genes is unknown. We conducted a retrospective study with 2080 children and young adults with AML registered on the Children\u2019s Oncology Group AAML0531 (NCT00372593) and AAML1031 trials (NCT01371981). Transcriptome profiling and\/or karyotyping were performed to identify leukemia-associated fusions associated with prognosis. Collectively, 127 patients (6.1%) were identified with MLLT10 fusions: 104 (81.9%) with KMT2A::MLLT10, 13 (10.2%) with PICALM::MLLT10, and 10 (7.9%) X::MLLT10: (2 each of DDX3X and TEC), with 6 partners (DDX3Y, CEP164, SCN2B, TREH, NAP1L1, and XPO1) observed in single patients. Patients with MLLT10 (n\u00a0= 127) demonstrated adverse outcomes, with 5-year event-free survival (EFS) of 18.6% vs 49% in patients without MLLT10 (n\u00a0= 1953, P\u00a0&amp;lt; .001), inferior 5-year overall survival (OS) of 38.2% vs 65.7% (P \u2264 .001), and a higher relapse risk of 76% vs 38.6% (P\u00a0&amp;lt; .001). Patients with KMT2A::MLLT10 had an EFS from study entry of 19.5% vs 12.7% (P\u00a0= .628), and an OS from study entry of 40.4% vs 27.6% (P\u00a0= .361) in those with other MLLT10 fusion partners. Patients with PICALM::MLLT10 had an EFS of 9.2% vs 20% in other MLLT10\u2212 without PICALM (X::MLLT10; P\u00a0= .788). Patients with PICALM::MLLT10 and X::MLLT10 fusions exhibit a DNA hypermethylation signature resembling NUP98::NSD1 fusions, whereas patients with KMT2A::MLLT10 bear aberrations primarily affecting distal regulatory elements. Regardless of the fusion partner, patients with AML harboring MLLT10 fusions exhibit very high\u2013risk features and should be prioritized for alternative therapeutic interventions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010805","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T21:11:40Z","timestamp":1706908300000},"page":"2005-2017","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Structural variants involving <i>MLLT10<\/i> fusion are associated with adverse outcomes in pediatric acute myeloid leukemia"],"prefix":"10.1182","volume":"8","author":[{"given":"Oussama","family":"Abla","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-946X","authenticated-orcid":false,"suffix":"Jr","given":"Tim","family":"Triche","sequence":"additional","affiliation":[{"name":"3Center for Epigenetics, Van Andel Institute, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[{"name":"4Children's Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Hirsch","sequence":"additional","affiliation":[{"name":"5Division of Laboratory Medicine, University of Minnesota Medical Center, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Raimondi","sequence":"additional","affiliation":[{"name":"6Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[{"name":"7Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-5839","authenticated-orcid":false,"given":"Jason E.","family":"Farrar","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Hematology-Oncology Section, Arkansas Children's Research Institute, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-3784","authenticated-orcid":false,"given":"Nathaniel","family":"Buteyn","sequence":"additional","affiliation":[{"name":"3Center for Epigenetics, Van Andel Institute, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Harmon","sequence":"additional","affiliation":[{"name":"3Center for Epigenetics, Van Andel Institute, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-4572","authenticated-orcid":false,"given":"Hong","family":"Wen","sequence":"additional","affiliation":[{"name":"3Center for Epigenetics, Van Andel Institute, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-9356","authenticated-orcid":false,"given":"Aniruddha J.","family":"Deshpande","sequence":"additional","affiliation":[{"name":"9Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"10Nemours Center for Cancer and Blood Disorders and Alfred I. DuPont Hospital for Children, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2893","authenticated-orcid":false,"given":"Alan S.","family":"Gamis","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"12Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Alonzo","sequence":"additional","affiliation":[{"name":"13Department of Translational Genomics, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"7Division of Hematology-Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"3","key":"2024042313253308800_bib1","first-page":"504","article-title":"Pediatric acute myeloid leukemia-past, present and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"12","key":"2024042313253308800_bib2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2024042313253308800_bib3","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/cncr.30791","article-title":"Decreased relapsed rate and treatment related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials","volume":"123","author":"Alexander","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2024042313253308800_bib4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3324\/haematol.2010.038976","article-title":"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2024042313253308800_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2024042313253308800_bib6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2024042313253308800_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"16","key":"2024042313253308800_bib8","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.22.02120","article-title":"Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster Study Group","volume":"41","author":"Van Weelderen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024042313253308800_bib9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2012.07.008","article-title":"PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients","volume":"36","author":"Borel","year":"2012","journal-title":"Leuk Res"},{"issue":"12","key":"2024042313253308800_bib10","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/leu.2013.149","article-title":"Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia","volume":"27","author":"Lo Nigro","year":"2013","journal-title":"Leukemia"},{"issue":"27","key":"2024042313253308800_bib11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myelid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024042313253308800_bib12","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2024042313253308800_bib13","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET Pediatric AML Study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024042313253308800_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08986.x","article-title":"EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia","volume":"157","author":"Grossmann","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"2024042313253308800_bib15","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3324\/haematol.2022.281653","article-title":"Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia","volume":"108","author":"Bertrums","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2024042313253308800_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 Multicentre Trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024042313253308800_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjh.13107","article-title":"Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy","volume":"168","author":"Karol","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2024042313253308800_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620715614529","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies","volume":"7","author":"Ommen","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"2024042313253308800_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fped.2019.00412","article-title":"Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: recent advances and future strategies","volume":"7","author":"Buldini","year":"2019","journal-title":"Front Pediatr"},{"issue":"28","key":"2024042313253308800_bib20","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children\u2019s Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024042313253308800_bib21","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2024042313253308800_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ncb1464","article-title":"Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L","volume":"8","author":"Okada","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2024042313253308800_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ccell.2014.10.009","article-title":"AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes","volume":"26","author":"Deshpande","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"2024042313253308800_bib24","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41594-023-01087-4","article-title":"CRISPR-ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia","volume":"30","author":"Gilan","year":"2023","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"2024042313253308800_bib25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3324\/haematol.2013.086082","article-title":"The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest","volume":"98","author":"Ben Abdelali","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2024042313253308800_bib26","first-page":"1000","article-title":"CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCR","volume":"102","author":"Asnafi","year":"2003","journal-title":"Neoplasia"},{"issue":"5","key":"2024042313253308800_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2013.101725","article-title":"DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia","volume":"99","author":"Brandimarte","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"2024042313253308800_bib28","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"7644","key":"2024042313253308800_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nature21687","article-title":"ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia","volume":"543","author":"Wan","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2024042313253308800_bib30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-023-37712-5","article-title":"MOZ\/ENL complex is a recruiting factor of leukemic AF10 fusion proteins","volume":"14","author":"Komata","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"2024042313253308800_bib31","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/2159-8290.CD-21-1307","article-title":"Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia","volume":"12","author":"Liu","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"2024042313253308800_bib32","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/leu.2014.235","article-title":"Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in\u00a0vitro","volume":"28","author":"Sarkaria","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2024042313253308800_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1L","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024042313253308800_bib34","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2021-144676","article-title":"A\u00a0global phase 2 study of valemetostat tosylate (Valemetostat) in patients with relapsed or refractory (R\/R) peripheral T-cell lymphoma (PTCL), including R\/R adult T-cell leukemia\/lymphoma (ATL) \u2013 Valentine-PTCL01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024042313253308800_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26697","article-title":"Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation","volume":"64","author":"Chijimatsu","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2024042313253308800_bib36","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTXO15 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coude","year":"2015","journal-title":"Oncotarget"},{"issue":"19","key":"2024042313253308800_bib37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/bloodadvances.2017006247","article-title":"MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs","volume":"1","author":"Maifrede","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"2024042313253308800_bib38","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res"},{"issue":"7954","key":"2024042313253308800_bib39","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"19","key":"2024042313253308800_bib40","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1158\/1078-0432.CCR-23-1003","article-title":"SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma","volume":"29","author":"Liu","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/2005\/2222801\/blooda_adv-2023-010805-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/2005\/2222801\/blooda_adv-2023-010805-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:25:47Z","timestamp":1713878747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/2005\/514803\/Structural-variants-involving-MLLT10-fusion-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010805","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}